Zobrazeno 1 - 5
of 5
pro vyhledávání: '"John David Rothermel"'
Autor:
John David Rothermel, J. Patrick O’Leary, Yi-Zarn Wang, Douglas A. Balster, P. Johnstone Maxwell, Lynn Harrison, Catherine T. Anthony, D. J. Frey, Eugene A. Woltering, James M. Lewis
Publikováno v:
Annals of Surgery. 237:790-800
A number of in vitro techniques have been developed to determine an individual tumor’s sensitivity to antineoplastics, hormones, and biologic response modifiers. Initially described by Salmon and Hamburger, the clonogenic or soft agar assay has bee
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f3ffd404e10708633a283885c2ec7c31
https://doi.org/10.1097/01.sla.0000072111.53797.44
https://doi.org/10.1097/01.sla.0000072111.53797.44
Autor:
Yu-Yun Ho, Chyi-Hung Hsu, Fisseha Tesfaye, Eric H. Rubin, Martine Hubert, John David Rothermel, Tianling Chen, Amit M. Oza
Publikováno v:
Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 23(36)
Purpose To evaluate the safety and maximum-tolerated dose (MTD) of weekly patupilone, a natural epothilone B, in patients with advanced solid tumors. Patients and Methods Patients were treated with patupilone (0.3 to 3.6 mg/m2) for 6 weeks on/3 weeks
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2afaf375c1d0e051abefd9537555b98d
https://pubmed.ncbi.nlm.nih.gov/16301592
https://pubmed.ncbi.nlm.nih.gov/16301592
Autor:
Rocio Garcia-Carbonero, Angela L. Campbell, Jeffrey G. Supko, David P. Ryan, Jeffrey W. Clark, Patricia LoRusso, Antoinette J. Wozniak, Joseph Paul Eder, Pamela DeLuca, Thomas A. Puchalski, John David Rothermel
Publikováno v:
Investigational new drugs. 22(2)
Purpose: 4′-N-Benzoyl-staurosporine (PKC412) is an orally available staurosporine derivative that inhibits protein kinase C. The objectives of this phase I trial were to determine the maximum tolerated dose (MTD), the dose limiting toxicities (DLTs
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ee71494fe77fcc6ce139d056317cda19
https://pubmed.ncbi.nlm.nih.gov/14739662
https://pubmed.ncbi.nlm.nih.gov/14739662
Publikováno v:
Seminars in oncology. 30(3 Suppl 6)
EPO906 (epothilone B) is a potent member of a new class of microtubule-stabilizing cytotoxic agents known as epothilones. Although structurally unrelated to the clinically validated taxanes, EPO906 acts similarly to promote the formation and stabiliz
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::407bec59ac48c4766ac6e56fb4da2ab1
https://pubmed.ncbi.nlm.nih.gov/12802795
https://pubmed.ncbi.nlm.nih.gov/12802795
Autor:
Brian M. Gebhardt, Yi-Zarn Wang, John David Rothermel, Catherine T. Anthony, P. Johnstone Maxwell, Paul M. J. Mcsheehy, Jessica L. Thompson, Eugene A. Woltering, James M. Lewis
Publikováno v:
Journal of the American College of Surgeons. 199:90
Introduction: We have previously shown that Epothilone B, a microtubule stabilizer, is a potent antiangiogenic in an intact human tumor-based angiogenesis assay. Clinical studies have demonstrated Epothilone B can be effective in patients resistant t
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::2be62572ddbebd4a1c9a8ca98fce96fe
https://doi.org/10.1016/j.jamcollsurg.2004.05.196
https://doi.org/10.1016/j.jamcollsurg.2004.05.196